2020

CANCER PROGRAM ANNUAL REPORT

PIH HEALTH
Table of Contents

Cancer Committee Membership
Cancer Program Highlights
Performance Improvement Initiatives
Program Goals
Clinical Goals
Cancer Registry
The PIH Health Whittier Hospital Cancer Committee is a multi-disciplinary team composed of medical staff members from diagnostic and therapeutic specialties, administrative staff and allied health professionals involved in the care of cancer patients. The committee members’ work together to provide the highest quality of care to cancer patients and play a key role in the success of PIH Health.

**PHYSICIAN MEMBERS**

- **Anthony Britto MD**  
  PLASTIC SURGEON

- **Armen Gregorian MD**  
  COLORECTAL SURGEON

- **Brent Gray MD**  
  ASSISTANT VICE PRESIDENT OF MEDICAL AFFAIRS (VPMA)/OB/GYN

- **Dustin E. Stevenson DO**  
  HEMATOLOGIST/MEDICAL ONCOLOGIST/CHAIR, CANCER COMMITTEE

- **Edwin Lin MD**  
  HEMATOLOGIST/MEDICAL ONCOLOGIST

- **Jack Freimann MD**  
  HEMATOLOGIST/MEDICAL ONCOLOGIST

- **Jeffrey Yuen MD**  
  RADIATION ONCOLOGIST

- **Kennith Thompson MD**  
  CO-MEDICAL DIRECTOR BREAST HEALTH CENTER/CANCER LIAISON PHYSICIAN/GENERAL SURGEON

- **Kimberly Bickell MD**  
  DIAGNOSTIC RADIOLOGIST/CO-MEDICAL DIRECTOR, BREAST HEALTH CENTER

- **Lisa S. Wang MD**  
  HEMATOLOGIST/MEDICAL ONCOLOGIST HEMATOLOGIST/MEDICAL ONCOLOGIST/MEDICAL DIRECTOR/CANCER LIAISON PHYSICIAN

- **Mark Odou MD**  
  SURGEON

- **Merrill Shum MD**  
  HEMATOLOGIST/MEDICAL ONCOLOGIST

- **Nadeem Chishti MD**  
  PULMONOLOGIST

- **Nathan Honda MD**  
  CHAIR, CANCER COMMITTEE, CANCER PROGRAM MEDICAL DIRECTOR/PATHOLOGIST

- **Robert Kleinman MD**  
  DIAGNOSTIC RADIOLOGIST

- **William Kurohara MD**  
  QUALITY CONTROL COORDINATOR OF REGISTRY DATA/RADIATION ONCOLOGIST

- **William MacDonald MD**  
  PATHOLOGIST
NON-PHYSICIAN MEMBERS

Andrea Allsup MSW
SOCIAL WORKER/PSYCHOSOCIAL ACTIVITY COORDINATOR

Alexa Giron BSN RN
BREAST NURSE NAVIGATOR

Breaz DeRousse
MARKETING COMMUNICATIONS

Cathy Zappia RN BSN PHN
SYSTEM MANAGER, AMERICAN CANCER SOCIETY

Claire McClafferty LCSW
PALLIATIVE CARE

Chantel K. Tanuvasa-Strotman, MSW
SOCIAL WORKER/PSYCHOSOCIAL ACTIVITY COORDINATOR

Dan Ogletree MSW
PALLIATIVE CARE

Daniel Patino-Ruiz
CANCER DATA SPECIALIST/CONFERENCE ACTIVITY COORDINATOR

Debbie McKnight RN MSN
ADMINISTRATIVE DIRECTOR, MED-SURGICAL SERVICES/ADMINISTRATOR

Gayle Madden-Mathes RN OCN
CLINICAL TRIALS RN

Genevieve Taguinod RN MSN NP
INFUSION CENTER MANAGER

Graciela Montes RN
DIRECTOR OF GROUP OPERATIONS, ADMINISTRATION

Ivonne Munoz RN BSN
DIRECTOR, BREAST HEALTH CENTER

Jenny Rodriguez MSW
SOCIAL WORKER/PSYCHOSOCIAL ACTIVITY COORDINATOR

Kathy Seymour RN BSN OCN
ONCOLOGY NURSE NAVIGATOR, CANCER PROGRAM

Kelly Sanchez RN MSN
ASSISTANT CLINICAL DIRECTOR, ONCOLOGY UNIT

Kenneth Endo MHA, BSRTT
CANCER PROGRAM CLINICAL DIRECTOR

Liz Gorski RN BSN
SURVIVORSHIP NAVIGATOR

Lucinda Place RN MSN
ADMINISTRATOR, QUALITY MANAGEMENT

Lynze Ruvalcaba RN BSN
CLINICAL DIRECTOR, ONCOLOGY UNIT

Maribel Ordorica RN
PRACTICE MANAGER, PIH HEALTH ONCOLOGY GROUP

Marie Cruz Garcia
CANCER REGISTRY

Miriam Turcios RN BSN
MANAGER, RADIATION ONCOLOGY

Monique Velasco DNP RN
LUNG NURSE NAVIGATOR

Ramona Pratt RN MSN MSHCA
CNO ONCOLOGY SERVICES

Raquel Varella PT/CLT
PHYSICAL THERAPIST, LYMPEDEMA PROGRAM

Regina Christ RN MSN NP
PALLIATIVE CARE

Rosie Drulias RN BSN PHN CCRP
CLINICAL TRIALS/CLINICAL RESEARCH ACTIVITY COORDINATOR

Sarah Merkle RN MSN AOCNS
CLINICAL DIRECTOR, CANCER PROGRAM / PI COORDINATOR

Sharice Johnson CTR
CANCER DATA SPECIALIST/CONFERENCE ACTIVITY COORDINATOR

Shelly Hart PTA-CLT
PHYSICAL THERAPIST LYMPEDEMA PROGRAM

Sovirny Preston
ADMINISTRATOR QM & PERFORMANCE EXCELLENCE

Sue Jervik RN BSN
PAIN MANAGEMENT EDUCATOR

Tammy Neu RN
CLINICAL DIRECTOR, HOSPICE

Thia Le, RD
MANAGER, CLINICAL NUTRITION

Vanessa Ivie
DIRECTOR, COMMUNITY BENEFIT AND COMMUNITY HEALTH

Vicky Wen
PHYSICAL THERAPIST LYMPEDEMA PROGRAM
2020 Cancer Program Highlights

2020 was an unprecedented year with the pandemic. Many program and initiatives were disrupted. Some programs were canceled and some became a virtual event.

The PIH Health Whittier Hospital Comprehensive Community Cancer Center provided a number of services to cancer patients in our community and beyond.

In the past, PIH Health participated in activities such as the American Cancer Society Relay for Life, Wig events such as partnering up with Vogue Wigs for cancer patients and survivors. Because of the pandemic, in-person activities were canceled or turned virtual.

The National Comprehensive Cancer Network (NCCN) distress tool was given to all appropriate patients at PIH Health undergoing cancer treatment in the infusion center and radiation oncology.

Survivorship Care Plan delivery continued to be a priority throughout 2020. The Survivorship Care Plan summarizes the patient's diagnosis, treatment plan and provided follow-up information and is essential for the continued journey into survivorship for cancer patients.

On November 10, 2020 we had a virtual nutrition workshop focused on cancer patients nutritional needs “Nutrition through treatment and beyond.” Facilitated by Liz Gorski BSN RN; Alexa Giron BSN RN and Cortney Kaller MDA RD.

On November 19, 2020, PIH Health raised awareness about the dangers of smoking by participating in the Great American Smokeout.
COMPLIMENTARY THERAPY

- The Mind Body Spirit Workshop, Yoga were placed on hold. The Women’s support group along with Journey Through Cancer Support groups went virtual in response to the pandemic.

CLINICAL TRIALS

In 2020, clinical trials continued to be an area of growth for the PIH Health Whittier Hospital. Offering clinical trials allows us to provide new approaches to treating and managing cancer. PIH Health is affiliated with SWOG, a global cancer research community that designs and conducts publicly funded clinical trials. Through this affiliation we have fourteen clinical trials actively accruing for various stages of breast, lung, kidney, colon, and rectal cancers. PIH Health also works with Translational Research in Oncology-US (TRIO-US). Through TRIO-US, PIH Health is able to offer further innovative clinical trial treatments to our community by collaborating with scientists, researchers, clinicians, and industry partners.

MARIPOSA BOUTIQUE

The Mariposa is a unique wellness boutique that helps patients return to a full and active life after surgery by introducing them to a wide range of products and services. Staff members include Certified Mastectomy Fitters who provide consultations on special breast prostheses and bras, and specialize in fitting lymphedema sleeves and compression medical wear. Women may obtain information on lymphedema, hospital and local support groups, and internet-based resources. Other items available for purchase include scarves, hats, wigs and jewelry. The services at Mariposa enable breast cancer patients and survivors to walk away feeling confident and beautiful.

CANCER SCREENING AND EARLY DETECTION

PIH Health is focused on wellness and illness prevention. Cancer screenings are designed to detect cancer early and decrease the number of late stage disease. The Cancer Program offered screening programs for breast, colon, and lung cancer. All screening programs are consistent with evidenced based guidelines. Due to the pandemic, the number of screenings were lower than the previous year.
COMMUNITY OUTREACH AND EDUCATION

The Cancer Committee worked with multiple internal departments and outside organizations to provide quality cancer care within our organization and throughout the community. Due to the pandemic, PIH Health offered one community outreach and educational activity during 2020, Smoking Cessation Workshop virtually.

- Breast Cancer Screening  
  » Performed with mammography  
  » 13360 screening mammographies performed  
- Colon Cancer Screening  
  » Performed via colonoscopy  
  » 1975 screening colonoscopies performed  
- Lung Cancer Screening  
  » Performed with a low-dose computed tomography (CT)  
  » 336 screening CT performed

ONCOLOGY RESOURCE CENTER

The Oncology Resource Center and Wig Bank are available for patients and their family members to access educational material and resources. Wigs and head coverings gifted to these women provide them dignity and compassion during their journey. In 2020 because of the pandemic only 8 wigs were distributed. The resources of the wig bank are made possible by the generosity and support of donors in our community.

Performance Improvement Initiatives  
Established in 2020

Initiating a tattoo less radiation therapy experience for breast cancer patients. The radiation therapy department eliminated the use of permanent tattoo’s for breast cancer patients. This helped patients with infection control, negative association of tattoo’s with cancer diagnosis and body image. 80% of patients receiving breast cancer treatment did not have to get tattoos.

Improving the quality of life for patients at the end of their life. Initiatives were put in place to help transition patients at the end of their life by controlling their pain, prevent hospitalization and to give appropriate levels of care to keep them comfortable.

PIH HEALTH AND AMERICAN CANCER SOCIETY (ACS)

- Women’s Cancer Support Group (virtual)  
- Journey Through Cancer Support Group (virtual)  
- Reach to Recovery – Peer-to-peer breast cancer support; 100% phone based. If you have breast cancer, you may want to connect with someone who knows what you’re feeling – someone who has “been there.” Through our Reach To Recovery website and app, you can have an online chat with a trained volunteer who has survived breast cancer and understands what you are going through.  
- Cancer Survivors Network – Online community by and for people with cancer and their families. Find and connect with others through our member search, discussion boards, chat rooms, and private CSN e-mail.  
- Springboard Beyond Cancer – Support community.  
- Belong – Beating Cancer Together – Belong is an app that provides people with cancer and their families a unique and innovative personalized solution to help manage care.
Cancer Registry

Established in 1987, the Cancer Registry is an essential component of the PIH Health Whittier Hospital Comprehensive Community Cancer Program. Our cancer database management system is designed to monitor all types of cancers diagnosed and/or treated at PIH Health and is a critical element in the evaluation of cancer care. Demographic information, cancer type, treatment and follow-up data are collected on each cancer patient by the registry staff, who are specially trained in the field of oncology data management. In 2020, the Cancer Registry database included data on 40,065 cases.

CANCER STATISTICS

- In 2020, 1,146 patients were diagnosed or received cancer care at PIH Health. These cases were diagnosed through the PIH Health service area (Figure 1)
- The most commonly diagnosed cancers detected and treated at PIH Health were compared to California cancer incidence and ranked according to frequency. Cancer incidence by gender at PIH Health was 494 males and 664 females. The incidence of breast cancer is higher at PIH Health compared to California rates. (Table 1). The Primary Site Distribution Table details PIH Health Whittier Hospital’s 2020 cancer experiences by site, age, gender, and stage of disease at diagnosis (Table 2).

2020 Cancer Incidence by Gender at PIH Health (Table 1)
The Primary Site Distribution Table details PIH Health Whittier Hospital’s 2020 cancer experiences by site, age, gender and stage of disease at diagnosis.

### Table 2

<table>
<thead>
<tr>
<th>Site Group</th>
<th>Total Cases</th>
<th>Class</th>
<th>NonAn</th>
<th>Other</th>
<th>Sex</th>
<th>Age</th>
<th>Stage 0</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
<th>UNK</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Head and Neck cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tongue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary Gland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gum, other Mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonsil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Buccal &amp; Pharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Digestive System</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL SITES</td>
<td>1172</td>
<td>940</td>
<td>212</td>
<td>20</td>
<td>14</td>
<td>664</td>
<td>236</td>
<td>104</td>
<td>58</td>
<td>54</td>
<td>121</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head and Neck cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Stage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Stage reflects analytic cases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AJCC Stage not applicable</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-applicable</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UNK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Stage reflects analytic cases  **AJCC Stage not applicable  NA = Non-applicable UNK = Unknown Stage
NUMBER OF NEW CANCER CASES 1987-2020

Figure 2 depicts the number of newly diagnosed cancer cases added to the Oncology Registry since 1989. These cases are categorized into three groups: new cancer cases for the year 2020; cases diagnosed and treatment given; and those diagnosed elsewhere, but received their initial treatment at PIH Health.

Figure 2

STAGE AT DIAGNOSIS

The stage of disease at the time of diagnosis plays a vital role in the prognosis and treatment of a cancer patient. In 2020, 44% of all newly diagnosed patients were in early stage at diagnosis (in-situ or Stage I), 16% were Stage II, 13% were Stage III, 21% were Stage IV, 15% were not applicable for staging (NA) and 7% were classified as unknown stage at time of diagnosis (Figure 3).

Figure 3
AGE DISTRIBUTION AT DIAGNOSIS

Seventy-three percent of patients were between the ages of 60 and 89 at diagnosis. The median age was 70 years. (Figure 4).

Figure 4
PHYSICIANS WHO PRESENTED AND PARTICIPATED IN CASE PRESENTATIONS AT CANCER CONFERENCES IN 2020

Daniel Akhavan MD
Ashwin Ashok MD
Kimberly Bickell MD
John Britto MD
Leo Buxnaum MD
Alfred Castellanos MD
Nadeem Chishti MD
Regina Christ NP
Dhand Sabeen MD
Jacques Dorce MD
Joel Garris MD
Armen Gregorian MD
Jack Freimann MD
Nathan Honda MD
Rodger C Hughes MD
Nassr Hussein MD
Samuel Im MD
Maureen Jensen MD
Robert Kleinman MD
Nanette Kovash DO
James Kuo MD
William Kurohara MD
Jason Lai MD
Edwin Lin MD
Shao-Pow Lin MD
William MacDonald MD
Rosemary Melesko NP
Paul O’Connor MD
Mark Odou MD

Renee Palta DO
Christie Pang MD
Joseph Park MD
Yong Park MD
Amish Patel MD
Anuj Rajput MD
Millicent Rovello MD
Daniel Saket MD
Kiumars Saketkhoo MD
Ravi Sankar MD
Dennis Sargent MD
Mukesh Shah MD
Neal Shindel MD
Merrill Shum MD
Joomee Shim MD
Dustin Stevenson DO
Eddie Thara DO
Kennith Thompson MD
Eduardo Tovar MD
Miguel Velez MD
Lilly Wang MD
Lisa Wang MD
G. Yoon MD
Brian Yue MD
Jeffrey Yuen MD
Scott Yun MD
Yunfei Wei MD
Maryam Zamanian MD
2020 BREAST, LUNG & MULTIDISCIPLINARY CANCER CONFERENCES AND LECTURE SUMMARY

Cancer conferences provide a multidisciplinary, patient specific, treatment-planning, consultative service for patients and their managing physicians. The conferences offer a forum for discussing various treatments options and assist in determining the most appropriate patient management plan.

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>104</td>
</tr>
<tr>
<td>Lung</td>
<td>118</td>
</tr>
<tr>
<td>Colorectal/Anus/Cecum</td>
<td>41</td>
</tr>
<tr>
<td>Stomach</td>
<td>5</td>
</tr>
<tr>
<td>Skin/Melanoma</td>
<td>3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>13</td>
</tr>
<tr>
<td>Ovary/Fallopian Tube</td>
<td>4</td>
</tr>
<tr>
<td>Corpus Uteri/Vulva/Endometrium</td>
<td>4</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>2</td>
</tr>
<tr>
<td>Unknown Primary</td>
<td>3</td>
</tr>
<tr>
<td>Bladder</td>
<td>1</td>
</tr>
<tr>
<td>Head &amp; Neck/Scalp</td>
<td>10</td>
</tr>
<tr>
<td>Thyroid</td>
<td>1</td>
</tr>
<tr>
<td>Leukemia/Myeloma</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>12</td>
</tr>
<tr>
<td>Kidney</td>
<td>2</td>
</tr>
<tr>
<td>Brain/CNS</td>
<td>6</td>
</tr>
<tr>
<td>Esophagus</td>
<td>4</td>
</tr>
<tr>
<td>Prostate</td>
<td>5</td>
</tr>
<tr>
<td>Small Intestine/Ileum</td>
<td>4</td>
</tr>
<tr>
<td>Testis</td>
<td>2</td>
</tr>
<tr>
<td>Nasopharyngeal</td>
<td>2</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>4</td>
</tr>
<tr>
<td>Appendix</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total # cases presented</strong></td>
<td><strong>352</strong></td>
</tr>
</tbody>
</table>
Acknowledgments

The 2020 PIH Health Comprehensive Community Cancer Program Annual Report was prepared by Nathan Honda, MD, Ken Endo MHA, BS RTT and Daniel Patino-Ruiz, CTR, and Marie Cruz Garcia under the purview of the Cancer Committee.

References

- Cancer Program Manual, 2020, American College of Surgeons Commission on Cancer, Chicago
- California Facts & Figures, 2020, American Cancer Society, California Division, Inc., Oakland, California
- PIH Health Cancer Registry Statistical Database

For more information about the PIH Health Comprehensive Community Cancer Program at PIH Health, call 562.698.0811 Ext. 12456, or visit PIHHealth.org
# Directory of Services

<table>
<thead>
<tr>
<th>Service</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Hospital Number</td>
<td>562.698.0811</td>
</tr>
<tr>
<td>Breast Oncology Nurse Navigator</td>
<td>562.907.0667 Ext. 15326</td>
</tr>
<tr>
<td>Cancer Program Education/Support Groups</td>
<td>562.698.0811 Ext. 12570</td>
</tr>
<tr>
<td>Cancer Information Hotline</td>
<td>562.945.8326</td>
</tr>
<tr>
<td>Cancer Registry</td>
<td>562.698.0811 Ext. 12896</td>
</tr>
<tr>
<td>Clinical Trials Department</td>
<td>526.698.0811 Ext. 12930</td>
</tr>
<tr>
<td>Colorectal Oncology Nurse Navigator</td>
<td>562.698.0811 Ext. 12580</td>
</tr>
<tr>
<td>Hospice of Presbyterian</td>
<td>562.947.3668</td>
</tr>
<tr>
<td>Home Health</td>
<td>562.902.7763</td>
</tr>
<tr>
<td>Infusion Services</td>
<td>562.698.0811 Ext. 12641</td>
</tr>
<tr>
<td>Lung Cancer Screening Program</td>
<td>562.967.2892</td>
</tr>
<tr>
<td>Lung Nurse Navigator</td>
<td>562.698.0811 Ext. 11271</td>
</tr>
<tr>
<td>Lymphedema Program</td>
<td>562.698.0811 Ext. 12594</td>
</tr>
<tr>
<td>Nutrition Services</td>
<td>562.698.0811 Ext. 11320</td>
</tr>
<tr>
<td>Oncology Resource Center</td>
<td>562.698.0811 Ext. 12820</td>
</tr>
<tr>
<td>Patricia L. Scheifly Breast Health Center</td>
<td>562.907.0667</td>
</tr>
<tr>
<td>PIH Health Hematology/Oncology Clinic</td>
<td>562.789.5480</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>562.696.5964</td>
</tr>
<tr>
<td>Website Address</td>
<td>PIHHealth.org</td>
</tr>
</tbody>
</table>
Glossary Of Terms

A = Analytic
Cases which are first diagnosed and/or received all or part of their first course of treatment at PIH Health Whittier Hospital.

N/A = Non-Analytic
Cases which were first diagnosed and treated elsewhere, later admitted to PIH Health with disease.

Stage at Diagnosis
The extent of disease based on all diagnostic and therapeutic evidence available by the end of the first course of therapy or within four months after beginning treatment.

NA
Not Applicable. Some types of cancer do not have staging schemes.

TNM Staging System
The TNM system is an expression of the anatomic extent of disease and is based on the assessment of three components:

- **T** The extent of the primary tumor
- **N** The absence or presence and extent of regional lymph node metastasis
- **M** The absence or presence of distant metastasis

TNM Stage Groupings
After the T, N and M has been assigned, they are grouped into stages. The grouping ensures, as far as possible, that each stage group is relatively homogeneous with respect to survival and that the survival rates of these stage groupings for each cancer site are distinct. Carcinoma in situ is categorized Stage 0; for most sites, a case with distant metastasis is categorized Stage IV. Stages I, II, and III indicate relatively greater anatomic extent of cancer within the range from Stage 0 to Stage IV.

Survival Rate
A statistical index that summarizes the probable frequency of specific outcomes for a group of patients at a particular point in time.

Life Table Method
The life table method involves dividing the total period over which a group is observed into fixed intervals, usually months or years.

Relative Survival
The ratio of the observed survival rate to the expected rate for a group of people in the general population similar to the patient group with respect to race, sex and age. The relative survival rate represents the likelihood that a patient will not die from causes associated specifically with their cancer at some specified time after diagnosis.